Ophthotech Corp (OPHT) 31.77 $OPHT
Healthcare Companies Report Clinical Study Results, Financial Results and Stock Summaries - Analyst Notes on Endocyte, Ophthotech, AcelRx Pharmaceuticals, bluebird bio, and Cantel Medical
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Endocyte, Inc. (NASDAQ: ECYT), Ophthotech Corporation (NASDAQ: OPHT), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), bluebird bio, Inc. (NASDAQ: BLUE), and Cantel Medical Corp. (NYSE: CMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Better Biotech Buy: Alexion Pharmaceuticals, Inc. vs. Regeneron
Dan Carroll, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Big biotech stocks like Alexion Pharmaceuticals and Regeneron have soared through the market's recent rally with flying colors. These two stocks alone each have captured more than 90% growth over that time, as climbing sales of top drugs have...
Who Will Capture This $3.5 Billion Opportunity?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:30PM CDT
Two of the most highly successful compounds to win FDA approval in the past few years have been Regeneron's Eylea and Novartis ' and Roche 's Lucentis. Both drugs help improve vision in patients who are losing their sight due to age or...
Ophthotech Corporation to Present at the 2014 Barclays Capital Global Healthcare Conference
Business Wire - Wed Mar 05, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Barclays Capital Global Healthcare Conference in Miami on Tuesday, March 11, 2014 at 9:30 a.m. Eastern Time.
Regeneron's Eylea: The Anatomy Of A Blockbuster Drug
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
Few drugs become multi-billion blockbusters, but those that do usually have similar characteristics. They treat big, and growing patient populations; they don't compete with too many other drugs (and outperform those that they do); and they have...
Nasdaq stocks posting largest percentage increases
AP - Tue Mar 04, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Ophthotech to Host R&D Day on March 7, 2014
Business Wire - Tue Mar 04, 6:30AM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced that the Company will host a live webcast in conjunction with its Research and Development (R&D) Day on Friday, March 7, 2014, beginning at 8:30 a.m. ET. A panel featuring leading retinal specialists will discuss the company's expanded clinical programs for Fovista(TM) anti-PDGF therapy in combination with anti-VEGF drugs for wet AMD. In addition, an update on Zimura(TM), an inhibitor of complement factor C5 for the dry and wet forms of AMD, will also be provided.
Ophthotech Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
Business Wire - Thu Feb 27, 5:00AM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business and product development programs.
The Global Aptamers Market was Valued at $287 Million in 2013 and is Expected to Reach $2.1 Billion by 2018
M2 - Wed Feb 26, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/zm94cc/aptamers_market) has announced the addition of the "Aptamers Market Technology Trend Analysis - Global Forecasts to 2018" report to their offering. The global aptamers market is anticipated to reach $2.1 billion by 2018 growing at a CAGR of 49.24%. The aptamers market is divided by geography (North America, Europe, Asia-Pacific and Rest of the World), application segments (therapeutics, diagnostics, biosensors, drug discovery, biomarker discovery, and research applications) and aptamer type (Nucleic acid aptamers and Peptide aptamers). Further each application segment and the aptamer type is broken down by geography, with exhaustive revenue analysis for the entire forecast period. Of the above mentioned application segments, research applications is the largest revenue segment; however, biomarker discovery and diagnostics will be the fastest-growing segment. The potential growth of the market is attributed to future diagnostics, drug discovery and research applications. The future approval of a few diagnostic tests specifically for infectious diseases and a couple of drugs in the market will greatly propel the market. The global market for aptamers is expected to grow, backed by technological advancements with respect to selection processes and synthesis. The market will experience continuous improvements in aptamer synthesis and its applicability in drug discovery and routine research. The market is witnessing a trend toward development of personalized medicine and point-of-care diagnostic tests. Additionally, the demand for safe and cost-effective drugs for treatment of cancer (which can be fulfilled by aptamer therapeutics), will remarkably fuel market growth. Companies Mentioned: - AM Biotechnologies, Llc - Aptagen, LIC - Aptamatrix, Inc - Aptamer Sciences Inc - Aptamer Solutions Ltd - Aptares AG - Aptusbiotech - Base Pair Biotechnologies - Bioapter SL - Cd Genomics - Integrated Dna Technologies, Inc - Lucerna, Inc - NOXXON Pharma AG - Neoventures Biotechnology Inc - OTC Biotech - Ophthotech Corporation - Pfizer - Regado Biosciences, Inc - Somalogic, Inc - Trilink Biotechnologies, Inc - Vivonics For more information visit http://www.researchandmarkets.com/research/zm...ers_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Ophthotech Corporation to Announce Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Thursday, February 27, 2014
Business Wire - Mon Feb 24, 7:55AM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced that its fourth quarter and year ended December 31, 2013, financial results will be released on Thursday, February 27, 2014. Following the announcement, Ophthotech's management will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update.
Ophthotech Corporation concludes public offering of common stock
M2 - Wed Feb 19, 5:30AM CST
US-based biopharmaceutical company Ophthotech Corporation (NasdaqGS:OPHT) revealed on Tuesday the completion of its public offering of 2,628,571 shares of its common stock.
Ophthotech Corporation Announces Closing of Registered Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Tue Feb 18, 3:01PM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today the closing of its previously announced registered public offering of 2,628,571 shares of its common stock at a price to the public of $31.50 per share, before underwriting discounts. Of the shares sold in the offering, 1,900,000 were sold by Ophthotech and 728,571 were sold by certain stockholders of the company. 342,857 of the shares sold by selling stockholders were sold as a result of the full exercise by the underwriters of a 30-day option to purchase these additional shares at the public offering price, less underwriting discounts.
4 Stocks Rising on Unusual Volume
at The Street - Thu Feb 13, 6:00AM CST
Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Ophthotech Corporation prices public offering at USD31.50 per common share
M2 - Wed Feb 12, 3:14AM CST
Biopharmaceutical company Ophthotech Corporation (NasdaqGS:OPHT) said on Tuesday that it has priced a public offering of 2,285,714 common shares at a public offering price of USD31.50 per share, before underwriting discounts.
Ophthotech Corporation Announces Pricing of Public Offering of Common Stock
Business Wire - Tue Feb 11, 9:29PM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today the pricing of an underwritten public offering of 2,285,714 shares of common stock at a public offering price of $31.50 per share, before underwriting discounts. Of the shares in the offering, 1,900,000 shares are being sold by Ophthotech, and 385,714 shares are being sold by certain stockholders of the company. In addition, these selling stockholders have granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 342,857 shares of the company's common stock at the public offering price, less the underwriting discount. Ophthotech will not receive any proceeds from the sale of shares by the selling stockholders.
Ophthotech Corporation plans public offering of 1.9m common shares
M2 - Tue Feb 11, 6:32AM CST
US-based biopharmaceutical company Ophthotech Corporation (NasdaqGS:OPHT) reported on Monday the start of an underwritten public offering of 1.9m shares of its common stock.
Ophthotech Corporation Announces Proposed Public Offering of Common Stock
Business Wire - Mon Feb 10, 6:25AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that it has commenced an underwritten public offering of 1,900,000 shares of its common stock. In addition, certain stockholders of the company are expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 285,000 shares of the company's common stock at the public offering price, less the underwriting discount. Ophthotech will not receive any proceeds from the sale of shares by the selling stockholders. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
Ophthotech Corporation secures USD41.7m from second tranche royalty financing agreement
M2 - Mon Jan 27, 5:37AM CST
US-based biopharmaceutical company Ophthotech Corporation (NasdaqGS:OPHT) reported on Friday the receipt of USD41.7m from a second tranche in royalty financing under a USD125m royalty agreement.
Ophthotech Corporation Receives $41.7 Million in Second Tranche in Royalty Financing from Novo A/S
Business Wire - Fri Jan 24, 6:30AM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced that it has received payment of approximately $41.7 million in a second tranche in royalty financing from Novo A/S. The receipt of the second tranche has been triggered as a result of Ophthotech reaching an initial enrollment milestone of a specified number of patients in its pivotal, multi-national Phase 3 clinical program of Fovista(TM), Ophthotech's anti-platelet-derived growth factor (PDGF) compound that is being studied in combination with anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related macular degeneration (wet AMD). Ophthotech initiated patient enrollment in the pivotal Phase 3 clinical program of Fovista in August 2013, and continues to expect to have initial top-line data in 2016.
Ophthotech Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 06, 6:29AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2014 at 10:30 a.m. Pacific Time (1:30 p.m. Eastern Time).
Healthcare Companies Report Clinical Study Results, Financial Results and Stock Summaries - Analyst Notes on Endocyte, Ophthotech, AcelRx Pharmaceuticals, bluebird bio, and Cantel Medical
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Endocyte, Inc. (NASDAQ: ECYT), Ophthotech Corporation (NASDAQ: OPHT), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), bluebird bio, Inc. (NASDAQ: BLUE), and Cantel Medical Corp. (NYSE: CMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Better Biotech Buy: Alexion Pharmaceuticals, Inc. vs. Regeneron
Dan Carroll, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Big biotech stocks like Alexion Pharmaceuticals and Regeneron have soared through the market's recent rally with flying colors. These two stocks alone each have captured more than 90% growth over that time, as climbing sales of top drugs have...
Who Will Capture This $3.5 Billion Opportunity?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:30PM CDT
Two of the most highly successful compounds to win FDA approval in the past few years have been Regeneron's Eylea and Novartis ' and Roche 's Lucentis. Both drugs help improve vision in patients who are losing their sight due to age or...
Ophthotech Corporation to Present at the 2014 Barclays Capital Global Healthcare Conference
Business Wire - Wed Mar 05, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Barclays Capital Global Healthcare Conference in Miami on Tuesday, March 11, 2014 at 9:30 a.m. Eastern Time.
Regeneron's Eylea: The Anatomy Of A Blockbuster Drug
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
Few drugs become multi-billion blockbusters, but those that do usually have similar characteristics. They treat big, and growing patient populations; they don't compete with too many other drugs (and outperform those that they do); and they have...
Nasdaq stocks posting largest percentage increases
AP - Tue Mar 04, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Ophthotech to Host R&D Day on March 7, 2014
Business Wire - Tue Mar 04, 6:30AM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced that the Company will host a live webcast in conjunction with its Research and Development (R&D) Day on Friday, March 7, 2014, beginning at 8:30 a.m. ET. A panel featuring leading retinal specialists will discuss the company's expanded clinical programs for Fovista(TM) anti-PDGF therapy in combination with anti-VEGF drugs for wet AMD. In addition, an update on Zimura(TM), an inhibitor of complement factor C5 for the dry and wet forms of AMD, will also be provided.
Ophthotech Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
Business Wire - Thu Feb 27, 5:00AM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business and product development programs.
The Global Aptamers Market was Valued at $287 Million in 2013 and is Expected to Reach $2.1 Billion by 2018
M2 - Wed Feb 26, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/zm94cc/aptamers_market) has announced the addition of the "Aptamers Market Technology Trend Analysis - Global Forecasts to 2018" report to their offering. The global aptamers market is anticipated to reach $2.1 billion by 2018 growing at a CAGR of 49.24%. The aptamers market is divided by geography (North America, Europe, Asia-Pacific and Rest of the World), application segments (therapeutics, diagnostics, biosensors, drug discovery, biomarker discovery, and research applications) and aptamer type (Nucleic acid aptamers and Peptide aptamers). Further each application segment and the aptamer type is broken down by geography, with exhaustive revenue analysis for the entire forecast period. Of the above mentioned application segments, research applications is the largest revenue segment; however, biomarker discovery and diagnostics will be the fastest-growing segment. The potential growth of the market is attributed to future diagnostics, drug discovery and research applications. The future approval of a few diagnostic tests specifically for infectious diseases and a couple of drugs in the market will greatly propel the market. The global market for aptamers is expected to grow, backed by technological advancements with respect to selection processes and synthesis. The market will experience continuous improvements in aptamer synthesis and its applicability in drug discovery and routine research. The market is witnessing a trend toward development of personalized medicine and point-of-care diagnostic tests. Additionally, the demand for safe and cost-effective drugs for treatment of cancer (which can be fulfilled by aptamer therapeutics), will remarkably fuel market growth. Companies Mentioned: - AM Biotechnologies, Llc - Aptagen, LIC - Aptamatrix, Inc - Aptamer Sciences Inc - Aptamer Solutions Ltd - Aptares AG - Aptusbiotech - Base Pair Biotechnologies - Bioapter SL - Cd Genomics - Integrated Dna Technologies, Inc - Lucerna, Inc - NOXXON Pharma AG - Neoventures Biotechnology Inc - OTC Biotech - Ophthotech Corporation - Pfizer - Regado Biosciences, Inc - Somalogic, Inc - Trilink Biotechnologies, Inc - Vivonics For more information visit http://www.researchandmarkets.com/research/zm...ers_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Ophthotech Corporation to Announce Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Thursday, February 27, 2014
Business Wire - Mon Feb 24, 7:55AM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced that its fourth quarter and year ended December 31, 2013, financial results will be released on Thursday, February 27, 2014. Following the announcement, Ophthotech's management will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update.
Ophthotech Corporation concludes public offering of common stock
M2 - Wed Feb 19, 5:30AM CST
US-based biopharmaceutical company Ophthotech Corporation (NasdaqGS:OPHT) revealed on Tuesday the completion of its public offering of 2,628,571 shares of its common stock.
Ophthotech Corporation Announces Closing of Registered Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Tue Feb 18, 3:01PM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today the closing of its previously announced registered public offering of 2,628,571 shares of its common stock at a price to the public of $31.50 per share, before underwriting discounts. Of the shares sold in the offering, 1,900,000 were sold by Ophthotech and 728,571 were sold by certain stockholders of the company. 342,857 of the shares sold by selling stockholders were sold as a result of the full exercise by the underwriters of a 30-day option to purchase these additional shares at the public offering price, less underwriting discounts.
4 Stocks Rising on Unusual Volume
at The Street - Thu Feb 13, 6:00AM CST
Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Ophthotech Corporation prices public offering at USD31.50 per common share
M2 - Wed Feb 12, 3:14AM CST
Biopharmaceutical company Ophthotech Corporation (NasdaqGS:OPHT) said on Tuesday that it has priced a public offering of 2,285,714 common shares at a public offering price of USD31.50 per share, before underwriting discounts.
Ophthotech Corporation Announces Pricing of Public Offering of Common Stock
Business Wire - Tue Feb 11, 9:29PM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today the pricing of an underwritten public offering of 2,285,714 shares of common stock at a public offering price of $31.50 per share, before underwriting discounts. Of the shares in the offering, 1,900,000 shares are being sold by Ophthotech, and 385,714 shares are being sold by certain stockholders of the company. In addition, these selling stockholders have granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 342,857 shares of the company's common stock at the public offering price, less the underwriting discount. Ophthotech will not receive any proceeds from the sale of shares by the selling stockholders.
Ophthotech Corporation plans public offering of 1.9m common shares
M2 - Tue Feb 11, 6:32AM CST
US-based biopharmaceutical company Ophthotech Corporation (NasdaqGS:OPHT) reported on Monday the start of an underwritten public offering of 1.9m shares of its common stock.
Ophthotech Corporation Announces Proposed Public Offering of Common Stock
Business Wire - Mon Feb 10, 6:25AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that it has commenced an underwritten public offering of 1,900,000 shares of its common stock. In addition, certain stockholders of the company are expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 285,000 shares of the company's common stock at the public offering price, less the underwriting discount. Ophthotech will not receive any proceeds from the sale of shares by the selling stockholders. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
Ophthotech Corporation secures USD41.7m from second tranche royalty financing agreement
M2 - Mon Jan 27, 5:37AM CST
US-based biopharmaceutical company Ophthotech Corporation (NasdaqGS:OPHT) reported on Friday the receipt of USD41.7m from a second tranche in royalty financing under a USD125m royalty agreement.
Ophthotech Corporation Receives $41.7 Million in Second Tranche in Royalty Financing from Novo A/S
Business Wire - Fri Jan 24, 6:30AM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced that it has received payment of approximately $41.7 million in a second tranche in royalty financing from Novo A/S. The receipt of the second tranche has been triggered as a result of Ophthotech reaching an initial enrollment milestone of a specified number of patients in its pivotal, multi-national Phase 3 clinical program of Fovista(TM), Ophthotech's anti-platelet-derived growth factor (PDGF) compound that is being studied in combination with anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related macular degeneration (wet AMD). Ophthotech initiated patient enrollment in the pivotal Phase 3 clinical program of Fovista in August 2013, and continues to expect to have initial top-line data in 2016.
Ophthotech Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 06, 6:29AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2014 at 10:30 a.m. Pacific Time (1:30 p.m. Eastern Time).
